Arcotatug tavatecan

坦康阿科妥塔单抗

Report date: 2026/04/16 20:00:17

Base Information

Drug NameArcotatug tavatecan
Drug Alias NameIBI-343IBI343
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker
Mechanisms of ActionAnti-CLDN18DNA topoisomerase I inhibitors
TargetsClaudin-18 splice variant 2DNA topoisomerase I
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Jiao Tong University School of MedicineHarbin Medical UniversityTakeda Pharmaceuticals International Ag +[5] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A